非偏头痛的头痛和肉毒毒素
Fatemeh Farham1, Dilara Onan2, Paolo Martelletti3
1Department of Headache, Iranian Centre of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran 1417653761, Iran.
Toxins
|October 25, 2024
概括
毒素A (BT-A) 提供了超越肌肉麻的治疗益处,通过抑制神经递质释放来有效控制疼痛. 本综述探讨了它在治疗各种头痛疾病的用途,包括慢性偏头痛.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 疼痛管理 疼痛管理
背景情况:
- 毒素A (BT-A) 是来自Clostridium botulinum的一种神经毒素,抑制了乙胆的释放,导致肌肉.
- BT-A具有多样化的治疗应用,新的证据表明,疼痛控制机制超出了神经肌肉阻塞.
- 这些机制包括抑制疼痛和炎症神经递质,如谷氨酸,CGRP和物质P,以及解决神经陷中的神经过敏症.
研究的目的:
- 提供关于肉毒素A在治疗初级和二级头痛疾病中的应用概述.
- 探索BT-A在疼痛管理中的机制,特别是在头痛中.
- 审查BT-A在头痛预防和治疗中的有效性.
主要方法:
- 对用于治疗头痛的肉毒素A现有研究的综述.
- 对BTA在疼痛和炎症中的作用机制的分析.
- 对治疗头痛的BT-A剂量和注射部位的临床数据的审查.
主要成果:
- 自2010年以来,BT-A已被批准用于慢性偏头痛预防.
- 研究表明,BTA在减少头痛频率和严重性的有效性.
- BT-A通过感官通路调节疼痛,这表明它对各种类型的头痛具有更广泛的适用性.
结论:
- 毒素A是一种有价值的治疗选择,用于管理头痛疾病.
- 它在慢性偏头痛预防中的有效性和对其他头痛的潜在作用需要进一步研究.
- 在神经疾病中,BT-A的多方面的机制为缓解神经疾病的疼痛提供了一个有希望的方法.
相关概念视频
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
656
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
656
01:31Skeletal Muscle Relaxants: Therapeutic Uses
468
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
468
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
395
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
395
01:21Skeletal Muscle Relaxants: Adverse Effects
338
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
338
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.7K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.7K
01:28Drugs Acting on Autonomic Ganglia: Blockers
967
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
967